Current Edition

clinical

Summit Therapeutics says PhaseOut DMD clinical trial did not meet primary endpoint

The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost …

Continue Reading →